Most maintenance professionals understand the value of routine oil analysis. However, in many organizations, the greatest threat to an established oil analysis program is not the absence of testing—it is the gradual extension of sampling intervals over time.
This situation, which is sometimes referred to as "sampling interval drift," occurs when a monthly sampling program becomes a 45-day program, or a quarterly program slowly extends to four or five months. While these changes often appear operationally insignificant, they can substantially reduce the effectiveness of predictive maintenance strategies.
Oil analysis is fundamentally a trending discipline. Its greatest value lies not in any individual laboratory result, but in the ability to identify gradual changes in wear rates, contamination levels, lubricant degradation, and equipment operating conditions over time. In other words, Predictive Maintenance. Once sampling intervals become inconsistent, trend integrity begins to deteriorate.
Studies of predictive maintenance programs consistently show that oil analysis can provide early warning of machine failure. However, this depends heavily on consistent sampling frequency.
The risks associated with delayed oil analysis extend beyond obtaining results later than planned. Organizations may experience:
- Reduced trend resolution and diminished ability to identify gradual failure mechanisms
- Losing the window that enables scheduled rather than emergency repairs
- Increased uncertainty regarding the timing and root cause of contamination
- Reduced confidence in corrective action effectiveness
- Greater potential for secondary equipment damage
An example is a gearbox with a 30-day sampling schedule. If one sample is delayed by 45 days, the next available data point may represent a 75-day operating period rather than the intended 30-day interval. During that time, increasing wear metal concentration, additive depletion, water contamination, and/or oxidation may progress significantly without detection. What would otherwise appear as a gradual trend over multiple samples may instead emerge as an apparent sudden failure.
This loss of trend resolution creates an additional challenge that is rarely discussed: maintenance teams lose the ability to accurately calculate rates of change. A rise in iron concentration from 50 ppm to 150 ppm has vastly different implications if it occurs over 30 days versus 90 days.
For organizations devoted to best-practice reliability, the true cost of delaying oil analysis is not the laboratory test itself. Rather, it is the loss of predictive visibility that enables maintenance teams to identify problems while corrective actions remain planned, controlled, and comparatively inexpensive.
In the end, the most valuable oil analysis sample is often not the one that reveals a problem—it is the one that confirms a trend before the problem becomes critical.
To get back on track, visit https://testoil.com/company/contact-us/; call 216-251-2510; or email testoil-sales@et.eurofinsus.com.
With more than 30 years of experience in the oil analysis industry, Eurofins TestOil focuses exclusively on assisting industrial facilities with reducing maintenance costs and avoiding unexpected downtime through oil and fuel analysis program implementation. As industry experts in diagnosing oil-related issues in equipment such as turbines, hydraulics, gearboxes, pumps, compressors and diesel generators, Eurofins TestOil provides customers with same-day turnaround on routine oil analysis testing.
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. Eurofins is the global leader in food, environment, pharmaceutical and cosmetic product testing, and in discovery pharmacology, forensics, advanced material sciences and agroscience Contract Research services. Eurofins is also a market leader in certain testing and laboratory services for genomics, and in the support of clinical studies, as well as in BioPharma Contract Development and Manufacturing. The Group also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.
With over 61,000 staff across a network of 940 laboratories in 59 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods. Eurofins Shares are listed on Euronext Paris Stock Exchange.
